Trial success a priority for new alliance

Syneos Health and AiCure announce partnership to optimize patient engagement

Register for free to listen to this article
Listen with Speechify
MORRISVILLE, N.C. & NEW YORK—Syneos Health, a contract research organization (CRO) which considers itself “the only fully integrated biopharmaceutical solutions organization,” and AiCure, an artificial intelligence (AI) and advanced data analytics company, announced in late 2019 a novel strategic partnership to drive faster, smarter trials to optimize patient engagement. This collaboration amplifies a pre-existing relationship and responds to increasing customer demand for digital solutions that change behaviors and improve patients’ lives.
The collaboration leverages AiCure’s proprietary intelligent software and AI-driven insights and Syneos Health’s behavioral insights-driven product development model in order to capture, analyze and predict patient behaviors influencing clinical trial adherence.
“The AiCure platform aligns with our unique product development model that harnesses behavioral insights to unlock real world experiences,” said Alistair Macdonald, CEO of Syneos Health. “By deploying the AiCure platform to our investigative sites, we create insights-enriched patient communities to advance clinical research. This collaboration reinforces [our philosophy] where we join forces with the latest and most agile data and technology partners to address our customers’ needs.”
Added Adam Hanina, CEO of AiCure: “Syneos Health’s first mover participation in our AiCure Partnerships for Excellence (AiPEX) program demonstrates the company’s dedication to the implementation of innovative technologies in clinical research. This full-service, collaborative delivery of AI to improve engagement, medication exposure, and achieve 360° access to clinical trial subjects, sites, and study insights represents our shared pursuit of therapeutic excellence. Syneos Health’s scale as a leading global CRO and the largest contract commercial organization will enable valuable customer engagements and expands our reach with biopharmaceutical companies of all sizes.”
Syneos Health will have access to AiCure’s digital biomarker assessments, evaluating facial, verbal, speech and and movement variables to objectively study known clinical endpoints. AiCure’s unique technology naturally inserts into the dosing interaction with the study subject while keeping all identifiable information secure and protected. The company, sponsors and site staff will also have access to dashboards with real-time, actionable and predictive data to improve decision making, facilitate timely interventions and achieve greater clinical trial operational efficiencies.

Published In:

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue